Acelyrin provides business and milestone update

Acelyrin provided an update on various corporate milestones. The ongoing Phase 3 trial of Izokibep in Hidradenitis Suppurativa, expected to be the first of two registrational trials, enrolled more rapidly than forecasted and enrollment is now completed with 258 patients. Top line data are now expected in Q3. For Lonigutamab in Thyroid Eye Disease, data from the ongoing Phase 1/2 proof-of-concept trial are continuing to be evaluated to determine the optimal dose and dose regimen for a Phase 2b/3 trial. This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024. For Izokibep in Uveitis, expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024. Early evaluation of SLRN-517 is ongoing. Expects to report cash, cash equivalents, and short-term marketable securities of $678.5M at March 31, 2024. Still expects cash position to fund operations into 2026 and is actively considering alternatives to further extend its cash runway. Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of Q3 and Q4, respectively.